Home » Regions » Global News » Abcodia, Oxford Gene Technology partner to advance pancreatic cancer biomarkers

Abcodia, Oxford Gene Technology partner to advance pancreatic cancer biomarkers

Wednesday, November 9, 2011

Abcodia, a company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, and Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, have signed a collaboration aimed at improving the early detection of pancreatic cancer.

As part of this collaboration, Abcodia will provide data mining expertise to deliver optimal sample sets from its large prospective serum biobank, taken from individuals up to 7 years before the diagnosis of pancreatic cancer. OGT will apply its functional protein array platform and its Genefficiency microRNA profiling array to identify pancreatic cancer specific biomarkers that can be used as diagnostic indicators of developing pancreatic cancer. Both OGT and Abcodia will bring their expertise in experimental design and analysis.

Julie Barnes, the chief executive Officer, Abcodia said: “We are very excited to be able to form this strategic partnership with OGT. The combination of the breadth of the OGT technology with our unique serum biobank provides a real opportunity to significantly advance the field of early pancreatic cancer diagnosis and screening. “

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!